Mobile

A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Re...

Update Il y a 4 ans
Reference: EUCTR2009-011206-42

A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Response to Any Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy including Biologics

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The Primary Objectives of this study are to determine the: • Safety and tolerability of 3 months of dosing of INCB028050 in patients with active rheumatoid arthritis who have had inadequate response to any DMARD therapy. • Efficacy of INCB028050 at 3 months in patients with active rheumatoid arthritis who have had inadequate response to any DMARD therapy.

Inclusion criteria

  • active rheumatoid arthritis

Links